ArticleAntimicrobial agents and chemotherapy2010
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 152 citations in OpenAlex.
- Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals.BMC infectious diseases · 2018Trial
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- High-riskHeliyon · 2025Article
- Tracing the origin of NDM-1-producing and extensively drug-resistant Pseudomonas aeruginosa ST357 in the Netherlands.BMC infectious diseases · 2024Article
- Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- The First Swedish Outbreak with VIM-2-ProducingMicroorganisms · 2023Article
- The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification.RSC medicinal chemistry · 2022Review
- Prevalence and analysis of CRISPR/Cas systems in Pseudomonas aeruginosa isolates from Greece.Molecular genetics and genomics : MGG · 2022Article
- Genomic-based transmission analysis of carbapenem-resistantJAC-antimicrobial resistance · 2022Article
- Emergence of Carbapenem-Resistant ST244, ST292, and ST2446Infection and drug resistance · 2022Article
- Whole-genome analysis of carbapenem-resistantComputational and structural biotechnology journal · 2022Article
- Article
- Diversity and Distribution of Resistance Markers inMicroorganisms · 2021Review
- Mobile Carbapenemase Genes inFrontiers in microbiology · 2021Review
- Article
- Unravelling the Features of Success of VIM-Producing ST111 and ST235Microorganisms · 2020Article
- Prevalence of Aminoglycoside Resistance Genes and Molecular Characterization of a Novel Gene,Antimicrobial agents and chemotherapy · 2020Article
- Molecular Epidemiology of Carbapenemase-ProducingInfection and drug resistance · 2020Article
- Dissemination of Carbapenem-Resistance among Multidrug ResistantInfection & chemotherapy · 2019Article
- Synthesis and biological evaluation of zinc chelating compounds as metallo-β-lactamase inhibitors.MedChemComm · 2019Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scandinavia is considered a region with a low prevalence of antimicrobial resistance. However, the number of multidrug-resistant (MDR) Gram-negative bacteria is increasing, including metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa. In this study MBL-producing P. aeruginosa isolates identified in Norway (n = 4) and Sweden (n = 9) from 1999 to 2007 were characterized. Two international clonal complexes (CC), CC111 (n = 8) and CC235 (n = 2), previously associated with MBL-producing isolates, were dominant. CC111 isolates (ST111/229; serotype O12; bla(VIM-2)) included clonally related isolates identified in Skåne County, Sweden (n = 6), and two isolates associated with importation from Greece and Denmark. In all CC111 isolates, bla(VIM-2) was located in integron In59.2 or In59 variants. The two CC235 isolates (ST235/ST230; serotype O11; bla(VIM-4)) were imported from Greece and Cyprus, were possibly clonally related, and carried bla(VIM-4) in two different integron structures. Three isolates imported from Ghana (ST233; serotype O6; bla(VIM-2)), Tunisia (ST654; serotype O11; bla(VIM-2)), and Thailand (ST260; serotype O6; bla(IMP-14)) were clonally unrelated. ST233 was part of a new CC (CC233) that included other MBL-producing isolates, while ST654 could also be part of a new CC associated with MBL producers. In the isolates imported from Ghana and Tunisia, bla(VIM-2) was part of unusual integron structures lacking the 3' conserved segment and associated with transposons. The bla(VIM) gene was found to be located on the chromosome in all isolates. Known risk factors for acquisition of MBL were reported for all patients except one. The findings suggest that both import of successful international clones and local clonal expansion contribute to the emergence of MBL-producing P. aeruginosa in Scandinavia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.